An Enabling Technology To Help Accelerate Translation From Concept To Clinic

MaxCyte's ExPERT Electroporation Platform revolutionizes cell therapy development with cutting-edge technology that supports efficient, scalable transfection for various cell types, including fragile and difficult-to-transfect cells. Leveraging 25 years of innovation, MaxCyte offers a clinically validated, GMP-compliant solution that seamlessly transitions from research to clinical manufacturing.

The platform’s Flow Electroporation® technology ensures highly efficient delivery of DNA, RNA, proteins, and other molecules into cells, enabling robust gene editing and therapeutic development. With pre-optimized protocols and support for both autologous and allogeneic workflows, it eliminates the need for re-optimization, reducing time-to-clinic.

MaxCyte’s system supports continuous scalability, processing from small-scale experiments (100,000 cells) to large-scale clinical manufacturing (up to 20 billion cells). Static and flow processing assemblies provide flexibility for different stages of development, while the platform’s GMP compliance ensures high-quality, reliable production.

Additionally, MaxCyte’s electroporation buffer and processing assemblies maintain cell viability and transfection efficiency, ensuring reproducibility and minimizing sample loss. The platform facilitates high-throughput processes for proof-of-concept studies, IND-enabling activities, and commercial production, streamlining the journey from concept to patient.

MaxCyte’s ExPERT platform empowers researchers and manufacturers with reliable, scalable solutions for cell therapy, helping to bring innovative treatments to patients faster while maintaining quality and efficiency across every stage of development.